IOP–lowering medications during pregnancy not linked to adverse neonatal outcomes
Taking intraocular pressure (IOP)–lowering medications during pregnancy was not associated with adverse neonatal outcomes, according to a study.
In this retrospective cohort study, 826 pregnant women with glaucoma were included. A total of 91 (11%) women in this study received IOP-lowering medications. The frequency of congenital anomalies (CA), preterm birth (PB), low birth weight (LBW), and the composite outcome of these measures between women with and without IOP-lowering medications, were compared.
In women on IOP-lowering medications, CA occurred in 9.9%, PB in 2.2%, LBW in 9.9%, and composite outcome in 17.6% compared to 6.4%, 4.5%, 6.0%, and 13.3%, respectively, in women without IOP-lowering medications.
Researchers concluded that in pregnant women, IOP-lowering medications were not significantly associated with higher rates of CA, PB, LBW, or composite outcome.
Hashimoto Y, Michihata N, Yamana H, et al. Intraocular pressure–lowering medications during pregnancy and risk of neonatal adverse outcomes: a propensity score analysis using a large database. Br J Ophthalmol. 2020; doi: 10.1136/bjophthalmol-2020-316198